Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Scientific Gets CE Mark for COVID-19, Flu A/B, RSV Kit

NEW YORK – Thermo Fisher Scientific said on Monday that it has received CE-marking for its TaqPath COVID-19, Flu A/B, RSV Combo Kit for the diagnosis of SARS-CoV-2, influenza A/B, and respiratory syncytial virus A/B infections.

The PCR-based kit allows laboratories to test for the diseases, which share clinical symptoms, in approximately three hours. Test results are analyzed using the Applied Biosystems Pathogens Interpretive Software, which automatically converts genetic analysis data into a report, reducing the risk of user interpretation error.

The new kit complements Thermo Fisher's previously launched TaqPath COVID-19 Combo Kit and RT-PCR CE-IVD.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.